List view / Grid view
Pfizer Inc. announced the positive results of a Phase 3…
17 July 2014 | By Pfizer
Pfizer Inc. announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B...
Pfizer Inc. announced top-line results from two pivotal Phase 3…
23 April 2014 | By Pfizer
Pfizer Inc. announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079)...
“We are excited to see progress in our development program…
9 October 2013 | By Pfizer Inc.
“We are excited to see progress in our development program in psoriasis..."
New data add to evidence supporting PRISTIQ as a treatment…
24 January 2013 | By Pfizer
New data add to evidence supporting PRISTIQ as a treatment option for MDD...
Top-line results of a Phase 3 study...
19 November 2012 | By Pfizer
Top-line results of a Phase 3 study...
Pfizer Inc., announced top-line results of a double-blind, placebo-controlled, Phase…
16 November 2012 | By Pfizer
Pfizer Inc., announced top-line results of a double-blind, placebo-controlled, Phase 3 study...
“These top-line data provide evidence of the long-term safety of…
11 October 2012 | By Pfizer
“These top-line data provide evidence of the long-term safety of ALO-02..."
Bapineuzumab IV Phase 3 program discontinued...
6 August 2012 | By Pfizer
Bapineuzumab IV Phase 3 program discontinued...
Co-primary clinical endpoints not met in study of patients with…
23 July 2012 | By Pfizer
Co-primary clinical endpoints not met in study of patients with Alzheimer’s disease who carry the ApoE4 genotype...
The EMA has accepted for review the MAA for bazedoxifene/conjugated…
19 July 2012 | By Pfizer
The EMA has accepted for review the MAA for bazedoxifene/conjugated estrogens...
Results of studies on Lyrica® announced...
18 May 2012 | By Pfizer
Results of studies on Lyrica® announced...
Pfizer has stopped a Phase 3 clinical trial of Lyrica…
4 May 2012 | By Pfizer
Pfizer has stopped a Phase 3 clinical trial of Lyrica in patients with neuropathic pain...
Dimebon did not meet primary efficacy endpoints...
17 January 2012 | By Pfizer
Dimebon did not meet primary efficacy endpoints...
New research collaboration will leverage data & experience to improve…
13 October 2011 | By Pfizer
New research collaboration will leverage data & experience to improve seniors’ well-being...
Pfizer Inc. announced that top-line results for Lyrica Study A0081107,…
21 June 2011 | By Pfizer
Pfizer Inc. announced that top-line results for Lyrica Study A0081107, demonstrated that the study met its primary endpoint...
